Vortioxetine: a New Treatment for Major Depressive Disorder.

Connolly, K Ryan; Thase, Michael E

Connolly, K Ryan; Thase, Michael E.

Affiliation

Connolly KR; a Philadelphia Veterans Affairs Medical Center , Philadelphia , PA , 19104 , USA.
Thase ME; b Department of Psychiatry , University of Pennsylvania , Philadelphia , PA 19104 , USA.

Expert Opin Pharmacother ; 17(3): 421-31, 2016.

Article in En | MEDLINE | ID: mdl-26679430

Subject(s)

Antidepressive Agents/therapeutic use; Depressive Disorder, Major/drug therapy; Piperazines/therapeutic use; Selective Serotonin Reuptake Inhibitors/therapeutic use; Sulfides/therapeutic use; Animals; Antidepressive Agents/pharmacokinetics; Antidepressive Agents/pharmacology; Constipation/chemically induced; Humans; Nausea/chemically induced; Piperazines/pharmacokinetics; Piperazines/pharmacology; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors/pharmacokinetics; Selective Serotonin Reuptake Inhibitors/pharmacology; Sulfides/pharmacokinetics; Sulfides/pharmacology; Vomiting/chemically induced; Vortioxetine

Key words

Vortioxetine; antidepressants; major depressive disorder (MDD); multimodal serotonin modulator; selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Sulfides / Selective Serotonin Reuptake Inhibitors / Depressive Disorder, Major / Antidepressive Agents Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Expert Opin Pharmacother Journal subject: FARMACOLOGIA Year: 2016 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google